News blog

Merck shutters RNAi research facility

Less than five years after betting $1.1 billion on the power of RNA-interference (RNAi) to treat disease, pharmaceutical powerhouse Merck is shutting down the San Francisco research facility it acquired when it purchased Sirna Therapeutics, a biotechnology firm that specialized in RNAi, in 2006.

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE